Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03907488
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:58.687917+00:00
Published At
2025-06-12T00:00:00+00:00
Record Updated At
2026-04-13
Results Posted At
2025-06-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT03907488"
protocolSection.identificationModule.officialTitle
"A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \u0026gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-06-12"

Study condition terms

  • Ann Arbor Stage III Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphocyte-Rich Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.